Atomo Diagnostics (ASX:AT1) Revenue: A$3.49 Mil (TTM As of Dec. 2025)


What is Atomo Diagnostics Revenue?

Atomo Diagnostics ASX:AT1 -5.56% Revenue is A$3.49 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Atomo Diagnostics's revenue for the six months ended in Dec. 2025 was A$2.13 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.49 Mil. Atomo Diagnostics's Revenue per Share for the six months ended in Dec. 2025 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01.

Warning Sign:

Atomo Diagnostics Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Atomo Diagnostics was -16.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -39.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Atomo Diagnostics's highest 3-Year average Revenue per Share Growth Rate was -12.60% per year. The lowest was -39.00% per year. And the median was -20.60% per year.

Atomo Diagnostics  (ASX:AT1) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Atomo Diagnostics Revenue Related Terms

Atomo Diagnostics Revenue Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics Revenue Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Revenue
Get a 7-Day Free Trial 6.72 12.34 2.54 4.09 3.25

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.92 2.16 1.89 1.36 2.13

ASX:AT1 vs ABT, SYK, MDT: Revenue Comparison

For the Medical Devices subindustry, Atomo Diagnostics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atomo Diagnostics Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's Revenue distribution charts can be found below:

* The bar in red indicates where Atomo Diagnostics's Revenue falls into.


Atomo Diagnostics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of A$3.49 Mil mean?
Atomo Diagnostics (ASX:AT1) has a Revenue of A$3.49 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' Revenue too high?
Atomo Diagnostics' current Revenue is A$3.49 Mil.
How does Atomo Diagnostics' Revenue compare to ABT and SYK?
Atomo Diagnostics' Revenue of A$3.49 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Atomo Diagnostics and its competitors. Atomo Diagnostics's current Revenue is A$3.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Revenue is A$3.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Revenue is A$3.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.